Dr. Harold J. Burstein on CDK4/CDK6 Inhibitor Abemaciclib in Breast Cancer

Harold J. Burstein, MD, PhD
Published: Saturday, Aug 06, 2016


Harold J. Burstein, MD, PhD, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute discusses the results of MONARCH1, which looked at abemaciclib as monotherapy in patients with ER-positive breast cancer, after chemotherapy for advanced disease.
 
CDK4/CDK6 inhibitors, like abemaciclib, are a new class of drugs being investigated in advanced ER-positive breast cancer, said Burstein
 
In the study, the drug was shown to be reasonably well tolerated with some mild neutropenia and some incidence of lower GI-toxicity and diarrhea.
 
Abemaciclib induced a response rate of 19% in this patient population. The median progression-free survival (PFS) was six months and the median overall survival (OS) was 17.7 months.    
 
 
SELECTED
LANGUAGE

Harold J. Burstein, MD, PhD, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute discusses the results of MONARCH1, which looked at abemaciclib as monotherapy in patients with ER-positive breast cancer, after chemotherapy for advanced disease.
 
CDK4/CDK6 inhibitors, like abemaciclib, are a new class of drugs being investigated in advanced ER-positive breast cancer, said Burstein
 
In the study, the drug was shown to be reasonably well tolerated with some mild neutropenia and some incidence of lower GI-toxicity and diarrhea.
 
Abemaciclib induced a response rate of 19% in this patient population. The median progression-free survival (PFS) was six months and the median overall survival (OS) was 17.7 months.    
 
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x